Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 32 of 32 results for daratumumab

  1. Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)

    Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

    Technology appraisal guidance
    Published
    3 December 2025
    View recommendations

    Sections for TA1114

  2. Two new treatment options for incurable blood cancer assessed

    We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.

    News
    Last updated
    9 August 2024